(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 October 2019 (17.10.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/199792 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)
C12Q 1/68 (2018.01)

(21) International Application Number:
PCT/US2019/026543

(22) International Filing Date:
09 April 2019 (09.04.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/655,648 10 April 2018 (10.04.2018) US

(71) Applicant: **REVOLUTION MEDICINES, INC.** [US/US]; 700 Saginaw Drive, Redwood City, California 94063 (US).

(72) Inventors: **WILDES, David E.**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **STAHLHUT-ESPINOSA, Carlos**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **NICHOLS, Robert J.**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US).

(74) Agent: **NUDELMAN, Aaron S.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: SHP2 INHIBITOR COMPOSITIONS, METHODS FOR TREATING CANCER AND METHODS FOR IDENTIFYING A SUBJECT WITH SHP2 MUTATIONS




Figure 7

(57) Abstract: The present disclosure provides methods of treating diseases or disorders related to mutations in the SHP2 gene using allosteric inhibitors of SHP2 and methods and diagnostic tests for identifying subjects susceptible or resistant to allosteric inhibitors of SHP2. In particular, the present disclosure provides allosteric inhibitor-sensitive mutations and allosteric inhibitor-resistant mutations of SHP2 for diagnostic and therapeutic use.

[Continued on next page]

WO 2019/199792 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*